Checchi Capital Advisers’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.07M Buy
9,863
+221
+2% +$224K 0.46% 52
2025
Q4
$10.4M Sell
9,642
-209
-2% -$200K 0.53% 44
2025
Q3
$7.52M Sell
9,851
-805
-8% -$599K 0.39% 56
2025
Q2
$8.31M Sell
10,656
-403
-4% -$313K 0.46% 51
2025
Q1
$9.13M Buy
11,059
+315
+3% +$262K 0.48% 46
2024
Q4
$8.29M Buy
10,744
+1
+0% +$828 0.48% 50
2024
Q3
$9.52M Sell
10,743
-234
-2% -$210K 0.53% 40
2024
Q2
$9.94M Buy
10,977
+111
+1% +$88.8K 0.5% 36
2024
Q1
$8.45M Buy
10,866
+46
+0.4% +$32.7K 0.66% 43
2023
Q4
$6.31M Sell
10,820
-347
-3% -$203K 0.51% 56
2023
Q3
$6M Sell
11,167
-100
-0.9% -$51.5K 0.56% 46
2023
Q2
$5.28M Buy
11,267
+71
+0.6% +$29.8K 0.47% 57
2023
Q1
$3.84M Buy
11,196
+169
+2% +$57K 0.37% 62
2022
Q4
$4.03M Sell
11,027
-52
-0.5% -$18.4K 0.42% 61
2022
Q3
$3.58M Buy
11,079
+33
+0.3% +$10.5K 0.33% 69
2022
Q2
$3.64M Sell
11,046
-412
-4% -$124K 0.32% 66
2022
Q1
$3.28M Buy
11,458
+1,672
+17% +$430K 0.28% 68
2021
Q4
$2.7M Buy
9,786
+122
+1% +$30.9K 0.24% 73
2021
Q3
$2.23M Buy
9,664
+167
+2% +$41.2K 0.22% 79
2021
Q2
$2.18M Sell
9,497
-414
-4% -$83.2K 0.21% 86
2021
Q1
$1.85M Sell
9,911
-195
-2% -$38.1K 0.18% 95
2020
Q4
$1.71M Buy
10,106
+156
+2% +$23.3K 0.18% 97
2020
Q3
$1.47M Sell
9,950
-294
-3% -$45.5K 0.16% 92
2020
Q2
$1.68M Sell
10,244
-439
-4% -$67.4K 0.2% 80
2020
Q1
$1.48M Buy
10,683
+233
+2% +$32K 0.14% 77
2019
Q4
$1.37M Sell
10,450
-108
-1% -$12.5K 0.18% 90
2019
Q3
$1.18M Sell
10,558
-112
-1% -$12.5K 0.15% 94
2019
Q2
$1.18M Sell
10,670
-680
-6% -$80.1K 0.15% 92
2019
Q1
$1.47M Sell
11,350
-185
-2% -$22.5K 0.17% 79
2018
Q4
$1.33M Sell
11,535
-745
-6% -$83.2K 0.17% 78
2018
Q3
$1.32M Buy
12,280
+1,287
+12% +$129K 0.15% 92
2018
Q2
$938K Buy
10,993
+282
+3% +$23.2K 0.12% 111
2018
Q1
$829K Buy
10,711
+196
+2% +$15.8K 0.11% 123
2017
Q4
$888K Buy
10,515
+186
+2% +$15.8K 0.12% 107
2017
Q3
$884K Sell
10,329
-110
-1% -$9.02K 0.09% 101
2017
Q2
$859K Sell
10,439
-864
-8% -$70.5K 0.09% 103
2017
Q1
$951K Sell
11,303
-818
-7% -$65.5K 0.11% 94
2016
Q4
$891K Sell
12,121
-43
-0.4% -$3.2K 0.12% 99
2016
Q3
$976K Buy
12,164
+294
+2% +$23.5K 0.11% 86
2016
Q2
$935K Sell
11,870
-703
-6% -$52.9K 0.11% 85
2016
Q1
$905K Buy
12,573
+604
+5% +$45.7K 0.2% 85
2015
Q4
$1.01M Buy
11,969
+794
+7% +$65.9K 0.25% 84
2015
Q3
$935K Buy
11,175
+392
+4% +$33.1K 0.25% 76
2015
Q2
$900K Buy
10,783
+787
+8% +$60K 0.24% 81
2015
Q1
$726K Buy
9,996
+881
+10% +$62.7K 0.21% 92
2014
Q4
$629K Buy
9,115
+1,014
+13% +$68.4K 0.24% 90
2014
Q3
$525K Buy
8,101
+1,601
+25% +$101K 0.22% 98
2014
Q2
$404K Buy
6,500
+408
+7% +$24.3K 0.18% 102
2014
Q1
$359K Buy
6,092
+902
+17% +$50.3K 0.22% 89
2013
Q4
$265K Buy
+5,190
New +$260K 0.21% 104

Other funds holding LLY

Checchi Capital Advisers's LLY Position: Q1 2026 in Review

Checchi Capital Advisers increased its Eli Lilly (LLY) stake by 2.3% in Q1 2026, buying an estimated $224K and bringing the position to 9,863 shares worth $9.07M. The position accounts for 0.46% of the portfolio, ranked #52.

Checchi Capital Advisers first reported a position in LLY in Q4 2013 and has held it in 50 quarters since. The position peaked at $10.4M in Q4 2025. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Checchi Capital Advisers held 9,863 shares of Eli Lilly worth $9.07M as of Q1 2026.
  • Checchi Capital Advisers bought 221 Eli Lilly shares in Q1 2026, an estimated $224K.
  • Eli Lilly made up 0.46% of Checchi Capital Advisers's portfolio in Q1 2026, its #52 holding.
  • Checchi Capital Advisers first reported a position in Eli Lilly in Q4 2013 and has held it in 50 quarters since.
  • Checchi Capital Advisers's Eli Lilly position peaked at $10.4M in Q4 2025.
  • 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Checchi Capital Advisers's 13F filing for Q1 2026, filed 4 May 2026.